Compositions of and methods for in vitro viral genome engineering
The present disclosure relates to a method of in vitro engineering of nucleic acids. This disclosure further relates to in vitro engineering of viral genomes and to the improvement of viral properties by in vitro genomic engineering of viral genomes. Specifically, the disclosure relates to in vitro viral genomic digestion using RNA-guided Cas9, the assembly of a recombinant genome by the insertion of a DNA or RNA fragment into the digested viral genome and transformation of a host cell with the recombinant genome. This method also related to in vitro engineering for error correction of nucleic acids.
1. A recombinant phage that expresses two or more payloads selected from the group consisting of a DNase, an exopolysaccharide (EPS) depolymerase, and one or more surfactant phenol soluble modulins.
2. The phage of claim 1 , wherein said two or more payloads comprise a DNase.
3. The phage of claim 1 , wherein said two or more payloads comprise an EPS depolymerase.
4. The phage of claim 1 , wherein said two or more payloads comprise a phenol soluble modulin.
5. The phage of claim 1 , wherein said two or more payloads comprise a DNase and an EPS polymerase.
6. The phage of claim 1 , wherein said two or more payloads comprise a DNase and a phenol soluble modulin.
7. The phage of claim 1 , wherein said two or more payloads comprise an EPS polymerase and a phenol soluble modulin.
8. The phage of claim 1 , wherein said two or more payloads comprise a DNase, an EPS polymerase, and one or more surfactant phenol soluble modulins.
9. The phage of claim 1 , wherein said phenol soluble modulin is selected from the group consisting of PSMa, PSMa3, and PSMb2.
10. The phage of claim 9 , wherein said phenol soluble modulin is PSMa.
11. The phage of claim 9 , wherein said phenol soluble modulin is PSMb2.
12. The phage of claim 9 , wherein said phenol soluble modulin is PSMa3.
13. The phage of claim 1 , wherein said phage is a phage that infects Pseudomonas aeruginosa.
14. The phage of claim 13 , wherein said phage is ΦKMV phage.
15. The phage of claim 14 , wherein said phage comprises a viral genome having at least 85% sequence identity to the LUZ19 genome.
16. The phage of claim 15 , wherein said phage comprises a LUZ19 viral genome.
17. The phage of claim 15 , wherein said phage comprises:
i) one or mutations selected from the group consisting of gp13 C17Y, gp18 D36Y, gp38 D82G and I83S, and gp40 N253D and shows improved host range compared to LUZ19; and/or
ii) a wildtype LUZ19 gp18 replaced with gp18 from virus LKD16; and/or
iii) a deletion of lysine at position 55 of gp34 (gp34L55Δ mutation) and said phage shows increase lytic activity compared to wild type LUZ19.
18. The phage of claim 17 , wherein said phage comprises one or mutations selected from the group consisting of gp13 C17Y, gp18 D36Y, gp38 D82G and I83S, and gp40 N253D and shows improved host range compared to LUZ19.
19. The phage of claim 18 , wherein said phage comprises a gp13 C17Y, mutation.
20. The phage of claim 18 , wherein said phage comprises a gp18 D36Y mutation.
21. The phage of claim 18 , wherein said phage comprises a gp38 D82G mutation.
22. The phage of claim 18 , wherein said phage comprises a gp38 I83S mutation.
23. The phage of claim 18 , wherein said phage comprises a gp38 I83S mutation.
24. The phage of claim 18 , wherein said phage comprises a gp40 N253D mutation.
25. The phage of claim 18 , wherein said phage comprises a gp13 C17Y mutation, a gp18 D36Y mutation, gp38 D82G and I83S mutation, and a gp40 N253D mutation.
26. The phage of claim 17 , wherein said phage comprises a wildtype LUZ19 gp18 replaced with gp18 from virus LKD16.
27. The phage of claim 17 , wherein said phage comprises a deletion of lysine at position 55 of gp34 (gp34 L55Δ mutation) and said phage shows increase lytic activity compared to wild type LUZ19.